Dry Eye Clinical Trial
Official title:
Comparison of the Effects of Two Tear Substitutes in Patients With Dry Eye Syndrome
Verified date | October 2017 |
Source | Huaxia Eye Hospital Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
With the potential to address evaporative dry eye, Liposic and Tears Naturale Forte have been developed in which phospholipid liposomes are delivered to the tear film via the surface of the closed eyelid. This study compare the effects of Liposic and Tears Naturale Forte application on the lipid and stability of the tear film in dry eye patients
Status | Completed |
Enrollment | 95 |
Est. completion date | January 25, 2018 |
Est. primary completion date | December 1, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 40 Years |
Eligibility |
Inclusion Criteria: - Age range from 20 year to 40 years - The value of OSDI is over 12 - NBUT is less 5 seconds - Schirmer 1 test is less 10mm - The basical lipid layer grade is 1-2 Exclusion Criteria: - Any corneal,conjunctival, or eyelid abnormalities; conjunctivitis; current ocular infection; photophobia that may cause reflex tearing or difficulty in evaluating the patien 's lipid layer; - Known allergic sensitivity to any of the ingredients in Liposic or Tears Naturale Forte |
Country | Name | City | State |
---|---|---|---|
China | Huaxia Eye Hosptial of Foshan | Foshan | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Huaxia Eye Hospital Group |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | scale of Schirmer I test | up to 3 months after tear substitutes apply | ||
Primary | scale of corneal fluorescein staining | up to 3 months after tear substitutes apply | ||
Primary | scale of noninvasive tear breakup time | up to 3 months after tear substitutes apply | ||
Primary | scale of tear meniscus height | up to 3 months after tear substitutes apply | ||
Primary | lipid layer grade | up to 3 months after tear substitutes apply | ||
Primary | questionnaire of ocular surface disease index | up to 3 months after tear substitutes apply | ||
Secondary | subjective comfort | up to 3 months after tear substitutes apply |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05027087 -
The Effect of a Novel Blueberry Supplement on Dry Eye Disease
|
Phase 3 | |
Completed |
NCT06159569 -
Performance and Tolerability of the Medical Device LACRIACT
|
N/A | |
Completed |
NCT05102409 -
An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease
|
Phase 2 | |
Completed |
NCT04081610 -
Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
|
Phase 1 | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT03418727 -
Dry Eye Disease Study With Brimonidine
|
Phase 2 | |
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT04527887 -
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
|
Phase 4 | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Active, not recruiting |
NCT05618730 -
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
|
Phase 1 | |
Completed |
NCT04553432 -
Dry Eye OmniLenz Application of Omnigen Research Study
|
Phase 4 | |
Recruiting |
NCT04109170 -
Dry Eye Evaluation System Based on Bioinformatics
|
||
Completed |
NCT04105842 -
Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type
|
N/A | |
Completed |
NCT05505292 -
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT04668131 -
Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease
|
N/A | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Not yet recruiting |
NCT02218827 -
Topical Steroid Treatment For Dry Eye
|
N/A | |
Completed |
NCT02235259 -
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
|
Phase 2 | |
Completed |
NCT01959854 -
Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye
|
N/A |